There are currently 212 clinical trials in Springfield, Illinois looking for participants to engage in research studies. Trials are conducted at various facilities, including Southern Illinois University School of Medicine, Memorial Medical Center, Springfield Clinic and Central Illinois Hematology Oncology Center. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
A Study of LY3537982 Plus Immunotherapy With or Without Chemotherapy in Participants With Non-Small Cell Lung Cancer (NSCLC) With a Change in a Gene Called KRAS G12C
Recruiting
The purpose of this study is to assess if adding LY3537982 in combination with standard of care anti-cancer drugs is more effective than standard of care in participants with untreated advanced NSCLC. NSCLC must have a change in a gene called KRAS G12C. Study participation, including follow-up, could last up to 3 years, depending on how you and your lung cancer are doing.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/25/2024
Locations: Springfield Clinic Main Campus, Springfield, Illinois
Conditions: Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis
Safety and Efficacy of ALXN1720 in Adults With Generalized Myasthenia Gravis
Recruiting
The purpose of this study is to evaluate the safety and efficacy of ALXN1720 for the treatment of generalized MG (gMG) in adults with autoantibodies against acetylcholine receptor (AChR).
Gender:
All
Ages:
18 years and above
Trial Updated:
04/25/2024
Locations: Research Site, Springfield, Illinois
Conditions: Generalized Myasthenia Gravis
A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)
Recruiting
The purpose of this study is to evaluate the efficacy of lepodisiran in reducing cardiovascular risk in participants with high lipoprotein(a) who have cardiovascular disease or are at risk of a heart attack or stroke. The study drug will be administered subcutaneously (SC) (under the skin).
Gender:
All
Ages:
18 years and above
Trial Updated:
04/25/2024
Locations: Central Illinois Diabetes and Clinical Research a Division of Prairie Education and Research Cooperative, Springfield, Illinois
Conditions: Atherosclerotic Cardiovascular Disease (ASCVD), Elevated Lp(a)
Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (PERSEUS)
Recruiting
Primary Objective: To determine the efficacy of SAR442168 compared to placebo in delaying disability progression in primary progressive multiple sclerosis (PPMS) Secondary Objectives: To evaluate efficacy of SAR442168 compared to placebo on clinical endpoints, magnetic resonance imaging (MRI) lesions, cognitive performance, physical function, and quality of life To evaluate safety and tolerability of SAR442168 To evaluate population pharmacokinetics (PK) of SAR442168 in PPMS and its relations... Read More
Gender:
All
Ages:
Between 18 years and 55 years
Trial Updated:
04/24/2024
Locations: Prairie Education and Research Cooperative Site Number : 8400071, Springfield, Illinois
Conditions: Primary Progressive Multiple Sclerosis
Primary Unloading and Delayed Reperfusion in ST-Elevation Myocardial Infarction: The STEMI-DTU Trial
Recruiting
The purpose of this research study is to evaluate whether using the the IMPELLA® CP System temporary circulatory assist device for 30 minutes prior to a catheterization procedure has the potential to reduce the damage to the heart caused by a heart attack, compared to the current standard of care.
Gender:
All
Ages:
Between 18 years and 85 years
Trial Updated:
04/24/2024
Locations: Southern Illinois University School of Medicine, Springfield, Illinois
Conditions: ST Elevation (STEMI) Myocardial Infarction of Anterior Wall
A Pivotal Study to Evaluate the Efficacy of Lorundrostat in Subjects With Uncontrolled Hypertension on a Standardized Antihypertensive Medication Regimen
Recruiting
a Phase 2 trial to evaluate the blood pressure-lowering effect of lorundrostat (an aldosterone synthase inhibitor), administered on a background of a standardized anti-hypertensive (AHT) medication regimen, in subjects with uncontrolled and/or treatment-resistant hypertension.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/24/2024
Locations: Southern Illinois School of Medicine, Springfield, Illinois
Conditions: Hypertension
A Phase 1b/2 Study of BGB-11417in Monotherapy and in Various Combinations With Dexamethasone and Carfilzomib in Multiple Myeloma
Recruiting
Study consists of two parts, a part 1 dose escalation and a part 2 cohort expansion in combination with dexamethasone and carfilzomib intravenously across two cohorts with a monotherapy component as well.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/24/2024
Locations: Southern Illinois University School of Medicine, Springfield, Illinois
Conditions: Relapsed/Refractory Multiple Myeloma
Efficacy and Safety of Lorundrostat in Subjects With Uncontrolled and Resistant Hypertension
Recruiting
This is a Phase 3 trial to evaluate the BP-lowering effect of lorundrostat (an aldosterone synthase inhibitor) in subjects with uncontrolled and resistant hypertension taking between 2 and 5 anti-hypertensive (AHT) medications.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/24/2024
Locations: Southern Illinois University School of Medicine - SIU Clinics - SIU Internal Medicine, Springfield, Illinois
Conditions: Hypertension
A Study of Tiragolumab Plus Atezolizumab Compared With Placebo Plus Atezolizumab in Participants With Completely Resected Non-small Cell Lung Cancer Who Have Received Adjuvant Platinum-based Chemotherapy
Recruiting
The purpose of this study is to evaluate the efficacy and safety of tiragolumab plus atezolizumab compared with placebo plus atezolizumab administered to participants with non-small cell lung cancer (NSCLC) following resection and adjuvant chemotherapy.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/24/2024
Locations: Springfield Clinic, Springfield, Illinois
Conditions: Non-small Cell Lung Cancer (NSCLC)
An Observational Research Study for Cancer Patients on Immune Checkpoint Inhibitors, DiRECT Study
Recruiting
This study compares treatment outcomes between patients of African American/Black (AA) ancestry and European American/White (EA) ancestry currently receiving immune checkpoint inhibitor treatment. Collecting samples of blood, saliva, stool, and health and treatment information from racially diverse patients receiving immune checkpoint inhibitor treatment over time may help doctors better understand healthcare disparities among all cancer patients.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/24/2024
Locations: Southern Illinois University School of Medicine, Springfield, Illinois +2 locations
Conditions: Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome
Recruiting
The purpose of this study is to evaluate that milvexian is superior to placebo, in addition to standard-of-care, in reducing the risk of major adverse cardiovascular event (MACE) (the composite of cardiovascular [CV] death, myocardial infarction [MI], and ischemic stroke).
Gender:
All
Ages:
18 years and above
Trial Updated:
04/23/2024
Locations: Prairie Cardiovascular Consultants, Ltd., Springfield, Illinois
Conditions: Acute Coronary Syndrome
A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation
Recruiting
The purpose of this study is to evaluate if milvexian is at least as effective as apixaban for reducing the risk of the composite stroke and non-central nervous system (CNS) systemic embolism.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/23/2024
Locations: Springfield Clinic 1st, Springfield, Illinois
Conditions: Atrial Fibrillation